Breast cancer drug, Lynparza, receives FDA approval
by Press Release from Outbreak News Today on (#3D8J3)
The U.S. Food and Drug Administration Friday expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast ["]
The post Breast cancer drug, Lynparza, receives FDA approval appeared first on Outbreak News Today.